Tau is not only a basic component of neurofibrillary degeneration, but is also an aetiological factor, as demonstrated by mutations on the tau gene responsible for frontotemporal dementias with parkinsonism linked to chromosome 17. Polymorphisms on the tau gene and the hierarchical invasion of neocortical areas by tau pathology in numerous sporadic neurodegenerative diseases also suggest that tau pathology is a primary pathogenic event in non-familial dementing diseases and a lead for solid diagnostic and therapeutic approaches. Curr
Introduction
The characterization and classi®cation of numerous neurodegenerative diseases have been dramatically improved after the discovery of molecular markers such as Ab, PrP, tau, alpha-synuclein. These markers are the basic components of speci®c brain lesions: amyloid plaques, prion plaques, tangles and Lewy bodies, respectively [1] . Tau pathology, or tauopathy, which are the molecular words for neuro®brillary degeneration, is a process affecting cortical and subcortical brain areas and is found in more than 20 different dementing disorders (Table 1) . Numerous familial tauopathies have recently been characterized. They have in common genetic defects on the tau gene, but clinical and neuropathological phenotypes are extremely heterogeneous. Understanding the basic mechanisms of tau pathology will certainly bring new opportunities for the diagnosis and treatment of most dementing disorders.
Tau pathology as a marker of neurofibrillary degeneration
Tau pathology corresponds to the intraneuronal aggregation of microtubule-associated tau proteins into abnormal 371 ®laments [2] . The normal role of tau is to stabilize microtubules, which are the tracks of the intraneuronal transport. There are six tau isoforms in the human brain that exhibit either three (3R) or four microtubulebinding domains (4R) (Fig. 1) . The three tau isoforms with 4R are more ef®cient than 3R tau isoforms in stabilizing microtubules. Conversely, phosphorylation of tau destabilizes microtubules, and it is suggested that abnormal phosphorylation, as observed in Alzheimer's disease (AD), provokes a collapse of the microtubule network. At the electron microscopic level, the ®lamen-tous material of neuro®brillary degeneration is either helical, twisted or straight, according to the neurodegenerative disorder ( A. Six different messenger RNAs are produced in the adult human brain, by alternative splicing. B. Consequently, six tau isoforms are expressed. Three of them have an additional repeat binding site to microtubules, corresponding to the sequence encoded by exon 10. C (left part). Alzheimer brain lesions (tangles, neuropile threads and dystrophic neurites of neuritic plaques) are composed of the six isoforms. They assemble into paired helical filaments (PHF) with a width of 8±20 nm and a periodicity of 80 nm. D. The biochemical signature of PHF is a class I profile, with a major triplet of electrophoretic band (tau 60, 64, 69). C' (right part). In frontotemporal dementia with parkinsonism linked to chromosome 17, many pathogenic mutations on the tau gene provoke the aggregation of three tau isoforms with four repeats. The three 4R tau isoforms aggregate into 15 nm wide twisted filaments with a crossover spacing of 130 nm. These filaments are found in neurons and astrocytes. D'. A class II biochemical signature (a major tau 64, 69 doublet) is observed. ]. These ®ndings demonstrate that the degenerating process can be balanced for a while (several years?) by a powerful compensating effect. They suggest that cofactors of AD, such as vascular factors [13±15], could weigh either on the pathology itself, or on the neuronal reservoir. Together, these observations could mean that neuroprotection can greatly in¯uence the fate of AD, either by slowing down the pathology or also by sustaining neuronal plasticity.
Because lesion antigens are overabundant at the infraclinical stage of AD, their detection in the cerebrospinal uid (CSF) could help to set up an early biological diagnosis. The simultaneous signi®cant increase of tau and decrease of Ab 1-42 levels in the CSF in AD is likely to be useful for clinical diagnosis in the near future [16] .
Tau pathology as an aetiological agent
The presence of brain lesions in neurodegenerative disorders usually arouses the same question: is this a cause or a consequence? Some answers are already available for tau pathology. The discovery that Tau mutations are directly involved in numerous FTDP-17 has been dramatically documented. More than 20 different mutations have been spotted. Familial diseases such as familial progressive subcortical gliosis also belong to the FTDP-17 group [17
. . ]. Most of the pathogenic mutations are responsible for an increase of 4R tau isoforms, giving a class II tau pathology (see Table 3 ). 4R tau isoforms, with the additional peptidic sequence of exon 10, have a much stronger af®nity towards microtubules than 3R isoforms, and an excess could modify microtubules, which will be stiffer and less dynamic. The other mutations are missense mutations that also affect microtubule polymerization and stability by decreasing tau±microtubule binding and lead to one of the class I, II, III tau pathologies (see Table 3 ). The striking feature of these familial tauopathies is the heterogeneity of the phenotype, which results from the different effects on tau (overexpression, loss of function). Early parkinsonism and stronger involvement of the substantia nigra are con®ned to mutations affecting the 3R : 4R tau isoform ratio [2±4,17
. . ,18
. . ]. Surprinsingly, for the same mutation in the same family, different onsets and different phenotypes can be observed ( Table 3) , showing that numerous additional factors can bring more heterogeneity to the phenotype.
We also noted that the neuropathological pro®le in FTDP-17 is quite different from AD, with a special involvement of astrocytes and cortical white matter, but also with an important heterogeneity for each mutation. Interestingly, but surprisingly, different groups have reported that numerous amyloid deposits were found in the brains of some young FTDP-17 patients [19, 25] . This is really puzzling and deserves further investigation.
However, not all diseases with a tau pathology have mutations on the tau gene. This has been veri®ed for CBD, PSP [46, 47] , amyotrophic lateral sclerosis/parkinsonism dementia complex of Guam [48] , and AD [49] .
Polymorphisms in progressive supranuclear palsy
Conrad and colleagues [50] identi®ed a polymorphic dinucleotide repeat sequence in a Caucasian population with PSP. This polymorphism, named A0, corresponding to an 11 TG dinucleotide repeat in intron 9 of the tau gene, is found in 95% of the PSP cohort (95.5%) and only in 57% of normal controls and 50% of patients with AD. Recently, these data were con®rmed by several studies and extended to a haplotype including a number of polymorphisms in linkage disequilibrium with A0 and named H1. This haplotype corresponds to A0 polymorphism, numerous single nucleotide polymorphisms along the entire tau gene and one intronic 238 bp deletion¯anking exon 10 [46, 51, 52, 53 . .
,54±58]. These polymorphisms may in¯uence exon 10 splicing and thus the proportion of 4R : 3R tau isoforms, leading to a class II tau pathology [59] . It should be noted that these A0 polymorphisms or H1 haplotypes were recently described in other pathologies including CBD and Parkinson's disease [60, 61] . Some other polymorphisms in the tau gene were also described as being associated with a risk of AD [62, 63] , but these data are still controversial [64] . ]. This hippocampal vulnerability is probably a springboard for Alzheimer pathology, namely amyloid precursor protein dysfunction, which will exacerbate and extend tau pathology in other brain areas [11, 66] . Together, neuropathological and biochemical data concur to indicate that tau pathology is instrumental in AD. In that respect, it should be pointed out that recent criteria for the neuropathological diagnosis have rehabilitated tau pathology [67] , in good agreement with Aloõ Ès Alzheimer observations and the natural history of AD.
The spread of tau pathology is also an important feature of other diseases, such as PSP and CBD, but the pathway is different, from subcortical to neocortical, mainly frontal and hippocampal areas [5, 68] . For all tauopathies, either sporadic or familial, the spread of neuro®brillary degeneration along speci®c neuronal populations probably relies on factors such as neuronal vulnerability and trophic factors. The characteristics of neuronal populations, and their vulnerability, could be driven partly by the speci®c sets of tau isoforms that they express. Analysing the factors that fuel the dynamic of tauopathy spreading in cortical areas will certainly give clues for neuroprotection [66] .
Conclusion
Tau pathology is an event occurring in all human brains, at least in the hippocampal region, and systematically after 75 years of age. Tau pathology is also observed in many dementing disorders. Some of them, such as AD, have a high prevalence. Tau gene defects are responsible for FTDP-17, and the tau gene also displays numerous polymorphisms that may contribute to the development of neuro®brillary degeneration. Therefore, the interest in tau pathology has increased dramatically in the past few years. At present, we need relevant experimental models to understand this many-sided degenerating process. Tau transgenic mice are already on the bench. Surprisingly, transgenic mice with a mutated APP gene, generating a load of Ab 20 times that found in the human brain, are reluctant to develop an extensive tau pathology. The explanation could be that the regulation of tau is more complex in the human brain [69 . ], and that age is an important factor (the main risk factor in AD), which cannot be used optimally with short-lived animals. 
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